(MedPage Today) — A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical Hodgkin lymphoma (cHL), with outcomes similar to younger patients but with a significant toxicity cost…
Source link : https://www.medpagetoday.com/hematologyoncology/lymphoma/116626
Author :
Publish date : 2025-07-22 20:18:00
Copyright for syndicated content belongs to the linked Source.
